Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks
Complex interaction of the sleep-wake cycle and circadian phase modulates mood in healthy subjects
Nature 380:435439 Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS et al (2003) The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis
Kimberly Gilbert, MD Medical Director, Balanced Aesthetics + Wellness